A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Brand Name :
AdreView
Synonyms :
iobenguane I-123
Class :
Diagnostic Imaging Agents
Dosage Forms & StrengthsÂ
SolutionÂ
2 millicurie/mlÂ
Gamma Scintigraphy
Administer dose of 10 millicurie intravenously
Begin whole body planar scintigraphy imaging 24 hours (plus or minus 6 hours) after administration
Congestive Heart Failure (CHF)Â
Administer dose of 10 millicurie intravenously
Begin anterior planar imaging of the chest at 4 hours (plus or minus 10 minutes) after administration
Administration
Administer intravenous infusion over 1 to 2 minutes, then flush with 0.9% sodium chloride to guarantee of complete administration of the dose
Dosage Forms & StrengthsÂ
SolutionÂ
2 millicurie/mlÂ
Gamma Scintigraphy
Start full body planar scintigraphy imaging 24 hours (plus or minus 6 hours) after administration
Congestive Heart Failure (CHF)Â
Gamma Scintigraphy
Start anterior planar imaging of the chest at 4 hours (plus or minus 10 minutes) after administration
Neonates <1 month: Safety and efficacy not determined
<16 years old and ≥70 kg: 10 millicurie
Children ≥16 years: follow as per adult dosing instructions
Administration
Administer intravenous infusion over 1 to 2 minutes, then flush with 0.9% sodium chloride to guarantee of complete administration of the dose
Refer to adult dosingÂ
Actions and SpectrumÂ
iobenguane I-123 is a radiolabelled analog of norepinephrine and acts as a radiotracer. It works by binding to norepinephrine transporters (NETs) on the surface of certain cells, particularly of the adrenal medulla and sympathetic nervous system.
Frequency not defined Â
DizzinessÂ
Injection site hemorrhageÂ
FlushingÂ
Pruritus Â
RashÂ
Post marketing ReportsÂ
HypersensitivityÂ
Black Box WarningÂ
None
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy consideration:Â
Pregnancy category: N/AÂ
Lactation: It is present in human breast milk Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology Â
iobenguane I-123 is a synthetic analog of norepinephrine, a neurotransmitter involved in the sympathetic nervous systems signaling. Â
Radiotracers are compounds that emit radiation that can be detected externally using specialized imaging equipment.Â
PharmacodynamicsÂ
iobenguane I-123 circulates in the bloodstream and is actively taken up by cells expressing NETs. In the adrenal medulla, it accumulates in specialized cells called chromaffin cells. Â
PharmacokineticsÂ
Absorption  Â
iobenguane I-123 administered intravenously, directly into the vein.Â
DistributionÂ
iobenguane I-123 distributes throughout the body.Â
MetabolismÂ
iobenguane I-123 is not significantly metabolized within the body. Â
Elimination and excretionÂ
iobenguane I-123 is excreted primarily through the kidneys. The half-life of drug is around 13.2 hours.Â
AdministrationÂ
iobenguane I-123 is administered as intravenous injection directly into a bloodstream.Â
Patient information leafletÂ
Generic Name: iobenguane I-123Â
Why do we use iobenguane I-123?Â
iobenguane I-123 is used for the imaging and evaluation of neuroendocrine tumors, particularly pheochromocytoma and paraganglioma. iobenguane I-123 is used for the evaluation of cardiac sympathetic innervation in patients with heart failure or certain arrhythmias.